CORMEDIX INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.195 USD | +0.10% |
|
-1.14% | +38.83% |
| Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
| Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the CorMedix Fo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.19
USD
Average target price
13
USD
Spread / Average Target
+150.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.83% | 285M | |
| +5.31% | 69.91B | |
| +10.97% | 9.03B | |
| -16.83% | 4.75B | |
| +43.48% | 4.31B | |
| +3.20% | 3.88B | |
| +18.82% | 2.37B | |
| -21.36% | 2.26B | |
| -29.67% | 2.2B | |
| +8.38% | 1.98B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- Transcript : CorMedix Inc., Q4 2021 Earnings Call, Mar 29, 2022
